Detalles de la búsqueda
1.
Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial.
Breast Cancer Res Treat
; 192(3): 593-602, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35138529
2.
Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study.
Breast Cancer Res Treat
; 187(3): 759-768, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33860389
3.
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Lancet Oncol
; 19(7): 904-915, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29804902
4.
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Breast Cancer Res
; 19(1): 16, 2017 02 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28183321
5.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Lancet Oncol
; 17(6): 791-800, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27179402
6.
Adjuvant trastuzumab in HER2-positive breast cancer.
N Engl J Med
; 365(14): 1273-83, 2011 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-21991949
7.
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.
Oncologist
; 18(7): 812-8, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23814044
8.
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Lancet Oncol
; 13(1): 25-32, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22153890
9.
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial.
Mol Oncol
; 16(12): 2355-2366, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34816585
10.
Is it appropriate to apply the enhanced recovery program to patients undergoing laparoscopic rectal surgery?
Surg Endosc
; 25(5): 1477-83, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21052724
11.
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.
Breast Cancer Res Treat
; 121(1): 121-31, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20339913
12.
Adherence to quality indicators and survival in patients with breast cancer.
Med Care
; 47(2): 217-25, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19169123
13.
Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial.
Asia Pac J Clin Oncol
; 14(1): 61-68, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28906589
14.
Clinicopathological analysis of malignant lymphoma in Taiwan, defined according to the World Health Organization classification.
Haematologica
; 90(12): 1703-5, 2005 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-16330450
15.
The global breast cancer burden: variations in epidemiology and survival.
Clin Breast Cancer
; 6(5): 391-401, 2005 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-16381622
16.
Transanal local wide excision for rectal adenocarcinoma.
Hepatogastroenterology
; 52(62): 460-3, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-15816457
17.
A General Cutoff Level Combined With Personalized Dynamic Change of Serum Carcinoembryonic Antigen Can Suggest Timely Use of FDG PET for Early Detection of Recurrent Colorectal Cancer.
Clin Nucl Med
; 40(10): e465-9, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26204213
18.
Locoregional failure of postmastectomy patients with 1-3 positive axillary lymph nodes without adjuvant radiotherapy.
Int J Radiat Oncol Biol Phys
; 52(4): 980-8, 2002 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-11958892
19.
Validating a prognostic scoring system for postmastectomy locoregional recurrence in breast cancer.
Int J Radiat Oncol Biol Phys
; 85(4): 953-8, 2013 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23122982
20.
Underperformance of gallium-67 scan is greater in relapse than in initial staging, compared with FDG PET.
Clin Nucl Med
; 36(10): 867-71, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21892035